IV Drip Therapy in Pakistani Clinics: Evidence, Oversight and Supplier Checks

In short: to our knowledge no single Pakistani standard is written for IV drip services, so a clinic is judged under general rules on licensing, medicines and advertising. Its position is strongest when it can show four things on paper: a physician-owned decision for each infusion, a licence that covers the service, a product registered with DRAP whose batch can be traced, and communication that makes no claim it has not been cleared to make.

Dawn reported in August 2026 that glutathione drips, used for cosmetic skin-tone purposes, are among the most sought-after aesthetic treatments in Pakistan, and that the country still lacks unified standards for licensing practitioners, approving procedures and monitoring products. For a clinic owner that gap offers no cover. It means the drip is judged under rules written for other things.

This article is the analytical companion to the IV Drip Guide, which grades the published evidence for each formulation class. It does not repeat those grades. It asks what the regulatory record of the past year means for everyday practice, and which documents a clinic should be able to produce if an inspector or a patient asks. It is general information from public sources, not legal advice.

The record of the past year

Public reports from August 2025 to August 2026 show enforcement on three fronts at once: the licensing of premises and practitioners, the status of the products used, and what is said publicly about them.

Two points stand out. First, most of the record concerns licensing, products and advertising in general rather than IV drips as such; the Kharian report is the one in which a drip is described being given. That is the point: an IV drip service is not examined as a special category but under the same rules as any clinic that handles injectable medicines. Second, most of these are press accounts, several of them secondary. The underlying texts, the DRAP Act and the Advertisement Rules, are public and are what a clinic should read.

What is in the bag, and why it matters

A drip is three things that are often sold as one: a base fluid, one or more additives, and a method of delivery. Most of the volume is fluid; the additive is the part that has a pharmacology and a label of its own. Reading a drip menu therefore means translating each named blend into a list of actives and asking what the evidence says about each one, not about the blend's name.

The IV Drip Guide does that for six formulation classes. Two features of its grading matter for a clinic's operations. The strong evidence for intravenous nutrients sits in documented deficiency, clinical nutrition and hospital care, and the controlled trials in sicker patients include no-benefit and harm signals (vitamin C in sepsis, glutamine in multiple organ failure), so the indication should drive the choice of product, not the menu. And elective use in well patients is graded limited or insufficient for every class, which is a reason to be modest about what is said of it.

The fluid itself deserves a sentence. A Cochrane review of children with gastroenteritis (Hartling et al., 2006) found no important clinical difference between oral and intravenous rehydration and recommended oral rehydration first in mild to moderate dehydration, with intravenous fluid if the oral route fails. The finding is in children with a specific illness and cannot be carried over to adults, but it shows why a faster route is not by itself a clinical advantage.

Menu wording is the second filter. A menu that lists ingredients describes a product. A menu that promises a result, such as an outcome for a named condition, makes a claim, and under the rules summarised below claims are where clinics meet the regulator.

Who is accountable for each infusion

Accountability is layered, and each layer has a document behind it.

• The physician. An infusion is a medical procedure. The decision to infuse, the choice of product and the assessment of the patient (allergies, renal and hepatic function, current medicines) belong to a physician registered with the PMDC. The Sindh commission's 2025 action in DHA turned on the absence of PMDC-registered dermatologists, and it warned that registered doctors lending their licences to unqualified operators would face disciplinary action.
• The premises. Clinics are licensed by the provincial healthcare commissions and, in Islamabad, by the Islamabad Healthcare Regulatory Authority under the Islamabad Healthcare Regulation Act, 2018. A licence is not generic: check that it covers the services the clinic lists.
• The product. In our reading, injectable preparations are medicines under the DRAP Act 2012, and Schedule II of the Act prohibits importing, manufacturing for sale or selling a therapeutic good that is not registered, unless an exemption applies. The clinic's link to that rule is its supplier file, described next.
• Sterile practice. Hand hygiene, aseptic preparation, catheter site care and single-use sets follow established standards: the Infusion Nurses Society's Infusion Therapy Standards of Practice (2021) and the US CDC guidelines on intravascular catheter-related infections (2011). They are international references, not Pakistani law, and they are the usual benchmark for good practice.
• Reaction and recall readiness. Anaphylaxis training and equipment on site, a written route for reporting suspected adverse reactions to DRAP's National Pharmacovigilance Centre, and a procedure for quarantining a batch.

The clinic file: what to be able to produce

The practical response to a standards gap is a file that does not depend on one. For each product in use, keep:

1. Registration evidence: the DRAP registration number with the registered name, strength and holder, the registration certificate, and a note of when and how the number was checked against DRAP's searchable list.
2. Supplier file: the supplier's Drug Sale Licence, the importer's authorisation from the manufacturer, and invoices that name the product and batch.
3. Batch record: batch number and expiry for each delivery, the date received, storage conditions and a temperature log where the label requires one.
4. Patient record: the assessment, the product and batch used, and any reaction.
5. Quarantine and recall note: who decides, where product is held, and how patients would be traced.
6. Communication policy: what the clinic publishes, who approves it, and the rule that nothing is published about a product that is not registered.

The questions to put to a supplier are set out in the guide under what to ask a supplier; the list above is what the clinic keeps once the answers are in. A clinic that cannot complete item 1 for a product has a reason to pause before using it.

What a clinic can say publicly

Under Schedule II-B of the DRAP Act, no one may advertise a therapeutic good, or a remedy or treatment for any disease, except in accordance with the prescribed conditions. The Act defines advertising as any representation made to promote, directly or indirectly, the sale or disposal of a therapeutic good, and exempts only the signboard of a clinic, dispensary or hospital.

The Therapeutic Goods (Advertisement) Rules, 2025 (S.R.O. 68(I)/2025) require the prior written permission of the Advertisement Board, and The News reported in February 2026 that DRAP said the rules are in full force. DRAP's advertisement guidelines go further for clinics: stating on a clinic website that a named prescription medicine is available at the clinic counts as advertising (guideline 11.2).

On our reading of these sources, a clinic website is most defensible when it describes the clinic, its licences and its services in general terms, and when drip menus, ingredient lists with brand names and outcome statements are not published. That is not legal advice; a clinic's legal adviser should confirm it against the current text.

Where EFBA stands

EFBA manufactures the IVIXIR range of professional IV formulations. IVIXIR products do not currently hold a DRAP registration, and IVIXIR products are supplied in Pakistan only after DRAP registration through a licensed importer; samples are not offered via this website. EFBA is looking for a licensed Pakistani importer to register them, as described on the distributors page. The formulations are listed in the catalogue (a short healthcare-professional confirmation applies). Nothing in this article is a claim about any IVIXIR product.